Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLSTAR: Futuximab/modotuximab + Trifluridine/Tipiracil in mCRC
NCT05223673Phase 3Terminated
- Sponsor
- Servier
- Start
- Apr 2022
- Primary completion
- Jun 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of futuximab + modotuximab in metastatic colorectal cancer (mCRC), sponsored by Servier. Started Apr 2022; status: terminated.
02
Drugs
futuximab + modotuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05223673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05223673.